Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 8, 2013, Pages 531-544

  Findling, Robert L ^a   Çavuş, Idil ^b   Pappadopulos, Elizabeth ^b   Vanderburg, Douglas G ^b   Schwartz, Jeffrey H ^b   Gundapaneni, Balarama K ^b   Delbello, Melissa P ^c  

^a JOHNS HOPKINS CHILDREN S CENTER   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; DIPHENHYDRAMINE; LORAZEPAM; PLACEBO; PROPRANOLOL; ZIPRASIDONE; ZOLPIDEM; ZOLPIDEM TARTRATE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADOLESCENT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY MASS; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; ELECTROCARDIOGRAPHY; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FOLLOW UP; HALLUCINATION; HOSTILITY; HUMAN; INSOMNIA; LACERATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDE; TREATMENT DURATION; TREMOR; VITAL SIGN; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; MALE; PIPERAZINES; PLACEBOS; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 84885969247     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0068     Document Type: Article

References (33)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Arlington, VA: American Psychiatric Association; 2004.
3. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
4. Beratis S, Gabriel J, Hoidas S: Age at onset in subtypes of schizophrenic disorders. Schizophr Bull 20:287-296, 1994.
5. Burd L, Kerbeshian J: A North Dakota prevalence study of schizophrenia presenting in childhood. J Am Acad Child Adolesc Psychiatry 26:347-350, 1987.
6. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491-505, 1999.
7. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144-158, 2011.
8. DelBello MP, Versavel M, Ice K, Keller D, Miceli J: Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 18:491-499, 2008.
9. Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49:583-594, 2010.
10. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S: Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22:327-342, 2012.
11. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
12. Guy W: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM) 76-338. Rockville, MD: National Institutes of Mental Health; 1976.
13. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V: Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 194:158-164, 2009a.
14. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009b.
15. Hafner H, Maurer K, Loffler W, Riecher-Rossler A: The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80-86, 1993.
16. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276, 1987.
17. Keck P, Jr., Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4- week placebo-controlled trial. Psychopharmacology (Berl) 140:173-184, 1998.
18. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K: Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160:741-748, 2003.
19. Keck PE, Jr., Versiani M, Warrington L, Loebel AD, Horne RL: Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 70:844-851, 2009.
20. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009.
21. Maayan L, Correll CU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517-535, 2011.
22. Masi G, Liboni F: Management of schizophrenia in children and adolescents: Focus on pharmacotherapy. Drugs 71:179-208, 2011.
23. Matzner F, Silva R, Silvan M, Chowdhury M, Nastasi L: Preliminary test-retest reliability of the KID-SCID, in 1997 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1997, pp 172-173.
24. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDAs pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007.
25. Potkin SG, Keck PE, Jr., Segal S, Ice K, English P: Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 25:301-310, 2005.
26. Poznanski EO, Freeman LN, Mokros HB: Childrens Depression Rating Scale-Revised. Psychopharmacol Bull 21:979-989, 1985.
27. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A childrens global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
28. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19, 1970.
29. Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D: A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179-1187, 2011.
30. Toren P, Ratner S, Laor N, Weizman A: Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 27:1135-1156, 2004.
31. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J: Ziprasidone in the treatment of acute mania: A 12-week, placebocontrolled, haloperidol-referenced study. J Psychopharmacol 24:547-558, 2010.
32. Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 24:112-117, 1988.
33. Young CM, Findling RL: Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother 4:53-60, 2004.